已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

上皮细胞粘附分子 癌症研究 抗体 双特异性抗体 免疫疗法 化学 癌症免疫疗法 肿瘤微环境 T细胞 单克隆抗体 免疫学 免疫系统 生物 肿瘤细胞
作者
Gerhard Frey,Ana Paula G. Cugnetti,Haizhen Liu,Charles Xing,Christina E. Wheeler,Hwai Wen Chang,William J. Boyle,Jay M. Short
出处
期刊:mAbs [Landes Bioscience]
卷期号:16 (1): 2322562-2322562 被引量:38
标识
DOI:10.1080/19420862.2024.2322562
摘要

Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that plays several roles in cancer biology. EpCAM is an attractive therapeutic target because of its expression in most solid tumors. However, targeting EpCAM has been challenging because it is also highly expressed in normal epithelial tissues. Initial attempts to develop EpCAM-specific T-cell engagers were unsuccessful due to severe cytokine release effects, as well as serious on-target, off-tumor drug-related toxicities. We developed novel, conditionally active biological (CAB) bispecific antibodies that bind to both EpCAM and CD3 in an acidic tumor microenvironment. In healthy tissues, binding to EpCAM and CD3 is greatly reduced by a novel, dual CAB selection, where each binding domain is independently blocked by the presence of physiological chemicals known as Protein-associated Chemical Switches (PaCS). The CAB anti-EpCAM T-cell engagers displayed the anticipated bispecific binding properties and mediated the potent lysis of EpCAM-positive cancer cell lines through the recruitment of T cells in the tumor microenvironment. Xenograft studies showed that the efficacy of CAB bispecific antibodies is similar to that of a non-CAB anti-EpCAM bispecific antibody, but they have markedly reduced toxicity in non-human primates, indicating an unprecedentedly widened therapeutic index of over 100-fold. These preclinical results indicate that the dual CAB bispecific antibody is potentially both a powerful and safe therapeutic platform and a promising T cell-engaging treatment for patients with EpCAM-expressing tumors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
3秒前
4秒前
体贴怡完成签到,获得积分10
6秒前
JamesPei的应助被listen采纳,获得30
6秒前
7秒前
hsj完成签到,获得积分10
8秒前
9秒前
haowei发布了新的文献求助10
9秒前
充电宝的应助被Rina采纳,获得10
11秒前
CipherSage的应助被Rina采纳,获得10
12秒前
Akim的应助被Rina采纳,获得10
12秒前
12秒前
英俊的铭的应助被Rina采纳,获得10
12秒前
所所的应助被心灵美的小伙采纳,获得10
12秒前
天天快乐的应助被Rina采纳,获得10
12秒前
852的应助被Rina采纳,获得10
12秒前
乐乐的应助被Rina采纳,获得10
13秒前
华仔的应助被天灵灵采纳,获得30
13秒前
英俊的铭的应助被Rina采纳,获得10
13秒前
NexusExplorer的应助被Rina采纳,获得10
13秒前
Jasper的应助被Rina采纳,获得10
13秒前
13秒前
14秒前
Waitcy发布了新的文献求助10
14秒前
14秒前
15秒前
17秒前
李博宇完成签到,获得积分10
18秒前
100毫升完成签到 ,获得积分10
21秒前
21秒前
故意的黑米完成签到,获得积分20
22秒前
listen发布了新的文献求助30
22秒前
郭子完成签到,获得积分10
22秒前
科研通AI6.3的应助被hkh采纳,获得10
22秒前
李博宇发布了新的文献求助10
22秒前
23秒前
24秒前
眼睛大淇完成签到,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194853
求助须知:如何正确求助?哪些是违规求助? 9580631
关于积分的说明 21872074
捐赠科研通 7794509
什么是DOI,文献DOI怎么找? 3437779
关于科研通互助平台的介绍 2561109
邀请新用户注册赠送积分活动 2484488